| Literature DB >> 30619050 |
Di Li1,2, Haixin Sun1,2, Xiaojuan Ru1,2, Dongling Sun1,2, Xiuhua Guo2,3, Bin Jiang1,2, Yanxia Luo2,3, Lixin Tao2,3, Jie Fu1,2, Wenzhi Wang1,2.
Abstract
Background: The leading cause of death in China is stroke, a condition that also contributes heavily to the disease burden. Nontraumatic intracerebral hemorrhage (ICH) is the second most common cause of stroke. Compared to Western countries, in China the proportion of ICH is significantly higher. Standardized treatment based on evidence-based medicine can help reduce ICH's burden. In the present study we aimed to explore the agreement between the management strategies during ICH's acute phase and Class I recommendations in current international practice guidelines in Beijing (China), and to elucidate the reasons underlying any inconsistencies found. Method: We retrospectively collected in-hospital data from 1,355 ICH patients from 15 hospitals in Beijing between January and December 2012. Furthermore, a total of 75 standardized questionnaires focusing on ICH's clinical management were distributed to 15 cooperative hospitals. Each hospital randomly selected five doctors responsible for treating ICH patients to complete the questionnaires.Entities:
Keywords: gap; international practice guidelines; intracerebral hemorrhage; management strategies; questionnaire
Year: 2018 PMID: 30619050 PMCID: PMC6297270 DOI: 10.3389/fneur.2018.01091
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Characteristics of ICH patients*.
| Age, years, mean (SD) | 60.7(13.6) |
| Male | 869 (64.1) |
| Living alone | 44 (3.2) |
| Elementary or below | 429 (31.7) |
| Middle school | 321 (23.7) |
| High school or above | 605 (44.6) |
| Hypertension | 933 (68.9) |
| Diabetes mellitus | 186 (13.7) |
| Hyperlipidaemia | 52 (3.8) |
| Stroke | 362 (26.7) |
| Atrial fibrillation | 145 (10.7) |
| Coronary artery disease | 113 (8.3) |
| Current smoker | 323 (23.8) |
| Current heavy drinker | 63 (4.6) |
| Overweight | 869 (64.1) |
| Antihypertensive therapy | 470 (34.7) |
| Antiplatelet therapy | 90 (6.6) |
| Warfarin | 18 (1.3) |
| Lipid-lowering therapy | 21 (1.5) |
| Hypoglycaemic therapy | 117 (8.6) |
| Time from symptom onset to hospital presentation < 5 h | 744 (54.9) |
| Systolic blood pressure | 172 (167–176) |
| Diastolic blood pressure | 95 (85–105) |
| Hemoglobin, g/DL | 140 (134–150) |
| White cell count, 109/L | 8.1 (6.1–9.4) |
| Platelets, 109/L | 209 (177–302) |
| INR | 0.9 (0.7–1.3) |
| Serum glucose, mmol/L | 7.9(5.7–11.2) |
| Basal ganglia | 629 (46.4) |
| Lobar | 272 (20.1) |
| Thalamus | 241 (17.8) |
| Brain stem | 86 (6.3) |
| Cerebellum | 81 (6) |
| IVH | 46 (3.4) |
| < 30 | 868 (66.3) |
| 30–60 | 231 (17.6) |
| >60 | 43 (3.3) |
| < 10 | 123 (9.4) |
| 10–20 | 34 (2.6) |
| >20 | 10 (0.8) |
| Intraventricular extension | 560 (42.9) |
IQR, interquartile range; INR, international normalized ratio; IVH, intraventricular hemorrhage; *Values are reported as mean ± SD, median (IQR), or number (percentage) of subjects.
≥4 drinks on any single day prior to stroke onset (a standard drink was defined as 12 fl oz of regular beer, 5 fl oz of table wine, or a 1.5–fl oz shot of 80-proof spirits).
Defined as body mass index (BMI) ≥24.
46 patients with IVH were excluded.
In-hospital management and outcomes of ICH patients.
| Transported to hospital by ambulance | 689 | 1,355 | 50.8 |
| Assessment NIHSS score on admission | 121 | 1,355 | 8.9 |
| Assessment GCS score on admission | 208 | 1,355 | 15.3 |
| CTA/MRA/CTV/MRV | 194 | 1,355 | 14.3 |
| Review of neuroimaging (CT/MRI) | 1,129 | 1,355 | 83.3 |
| Coagulopathy | 28 | - | - |
| Reversal therapy by one or more of platelet, vitamin K, FFP, and PCCs | 19 | 28 | 67.9 |
| Bedridden within 48 h after onset | 991 | - | - |
| One or more of IPC and ES | 221 | 991 | 22.3 |
| Treated at the Neuro-ICU | 193 | 1,355 | 14.2 |
| Treated at the Stroke unit | 66 | - | - |
| Treated at the Neurology ward | 458 | - | - |
| Treated at the Neurosurgery ward | 473 | - | - |
| Random blood glucose ≥11.1 mmol/L on admission | 343 | ||
| Glucose monitoring within 24 h of onset | 302 (22.3) | 343 | 88.0 |
| Received hypoglycemic therapy mainly with insulin | 267 (19.7) | 343 | 77.8 |
| Clinical seizures or electroencephalography seizures | 61 | - | - |
| Patients presented with seizures received antiepileptic treatment | 56 | 61 | 91.8 |
| Patients presented without seizures received prophylactic antiepileptic treatment | 95 | - | - |
| Indications for surgery | 22 | - | - |
| Received surgery | 11 | 22 | 50.0 |
| 0–2 | 429 | 1,355 | 31.7 |
| 3–5 | 594 | 1,355 | 43.8 |
| 6 | 332 | 1,355 | 24.5 |
| Health education | 950 | 1,023 | 92.9 |
| Antihypertensive treatment | 595 | 704 | 84.5 |
NIHSS, National Institutes of Health Stroke Scale; GCS, Glasgow Coma Score; CTA, CT angiography; CTV, CT venography; MRA, magnetic resonance angiography; MRV, magnetic resonance venography; CT, computerized tomography; MRI, magnetic resonance imaging; FFP, fresh frozen plasma; PCC, prothrombin complex concentrates; DVT, deep vein thrombosis; IPC, intermittent pneumatic compression; ES, elastic stockings; Neuro-ICU, neurological intensive care unit.
Defined as platelet ≤ 70.
Characteristics of cooperative hospital related to ICH management.
| Emergent green channel for ICH | 9 (60) |
| Neuro-ICU | 10 (66.7) |
| CT | 15 (100) |
| MRI | 15 (100) |
| Platelets | 15 (100) |
| FFP | 14 (93.3) |
| PCCs | 3 (20) |
| rFVIIa | 1 (6.7) |
| ES | 12 (80) |
| IPC | 14 (93.3) |
| EEG | 15 (100) |
| Bedside EEG | 8 (53.3) |
ICH, intracerebral hemorrhage; Neuro-ICU, neurological intensive care unit; CT, computerized tomography; MRI, magnetic resonance imaging; FFP, fresh frozen plasma; PCCs, prothrombin complex concentrates; rFVIIa, recombinant activated human coagulation factor VII; IPC, intermittent pneumatic compression; ES, elastic stockings; EEG, electroencephalogram.
Values are reported as number (percentage) of subjects.
Characteristics of doctor questionnaire respondents.
| Male | 40 (53.3) |
| 20–40 | 59 (78.7) |
| 41–60 | 16 (21.3) |
| Graduate | 18 (24) |
| Master | 43 (57.3) |
| Doctor | 14 (18.7) |
| Neurology | 45 (60) |
| Neurosurgery | 30 (40) |
| Junior | 26 (34.7) |
| Intermediate | 27 (36) |
| Senior | 22 (29.3) |
Values are reported as number (percentage) of subjects.
Results of the 10-item questionnaire to assess the perceived as important of the AHA guideline recommendations.
| Rapid neuroimaging assessment | 0 | 0 | 4 (5.3) | 71 (94.7) |
| Rapid hemostasis/antiplatelet treatment for deficiency | 1 (1.3) | 1 (1.3) | 29 (38.7) | 44 (58.7) |
| Rapid correction of coagulopathy | 0 | 0 | 16 (21.3) | 59 (78.7) |
| Deep vein thrombosis prophylaxis | 0 | 3 (4.0) | 29 (38.7) | 43 (57.3) |
| Treatment in Neuro-ICU | 1 (1.3) | 28 (37.3) | 11 (14.7) | 35 (46.7) |
| Glucose monitoring and normoglycemia | 0 | 1 (1.3) | 14 (18.7) | 60 (80) |
| Antiepileptic therapy for clinical seizures | 3 (4.0) | 3 (4.0) | 12 (16) | 57 (76) |
| Antiepileptic therapy for electrographic seizures | 1 (1.3) | 6 (8) | 19 (25.4) | 49 (65.3) |
| Neurosurgery for severe cerebellum hematoma | 0 | 0 | 21 (28) | 54 (72) |
| Antihypertensive treatment for prevention of recurrent ICH | 0 | 0 | 1 (1.3) | 74 (98.7) |
A, represents no reason to be done; B, represents could be done or not; C, represents should be done; D, represents must be done.
Values are reported as number (percentage) of subjects.
represents the question: should the following items be conducted for ICH patients?
Subgroup analyses comparing total scores of participants for each item.
| Graduate ( | 32.6 ± 2.9 | ||
| Master ( | 33.1 ± 2.3 | 0.49 | 0.61 |
| Doctor ( | 33.4 ± 2.7 | ||
| Neurology ( | 35 (34–39) | −1.690 | 0.091 |
| Neurosurgery ( | 39 (36–40) | ||
| Junior ( | 33 (31–34) | ||
| Intermediate ( | 34 (32–36) | 3.36 | 0.187 |
| Senior ( | 34 (31.5–35) | ||
IQR, interquartile range.